Molecular genetics of radiographically defined de novo glioblastoma multiforme

A. Tortosa, Y. Ino, N. Odell, S. Swilley, Hikaru Sasaki, D. N. Louis, J. W. Henson

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Glioblastoma multiforme (GBM) represents the final endpoint of anaplastic progression in astrocytomas. GBM which arise without clinical evidence of a prior low-grade astrocytoma (LGA) have been designated de novo GBM, and are thought to develop rapidly from initial tumour formation. However, a purely clinical definition of de novo GBM does not exclude a longstanding, asymptomatic low-grade tumour. This study therefore sought to determine the genetic features of a unique group of cases in which GBMs were documented to have arisen radiographically in defined period of time (radiographically defined de novo GBM). Clinical and genetic features were examined in a group of 11 patients with a histological diagnosis of high-grade astrocytoma at first biopsy and radiographically defined de novo GBM. The mean age of the patients at tumour diagnosis was 62 years (range 32-87). Six of 11 tumours arose in the temporal lobes. Eight of 11 tumours had epidermal growth factor receptor (EGFR) overexpression, and EGFR gene amplification was found in five of the six analysed cases. Overexpression of p53 was observed in only one tumour, and a TP53 mutation was present in this case. p16 immunostaining was undetectable in 10 cases, and homozygous deletion of CDKN2A was observed in four of the six studied tumours, pRb expression was lost in four tumours. Mutations in the PTEN gene were detected in two of six cases. The results in this unique group of cases confirms the prior hypothesis that the profile of genetic alterations in de novo GBM is distinct from that of GBM arising from a known LGA, and that these Specific genetic pathways promote the rapid development of CBM.

Original languageEnglish
Pages (from-to)544-552
Number of pages9
JournalNeuropathology and Applied Neurobiology
Volume26
Issue number6
DOIs
Publication statusPublished - 2000 Dec 1
Externally publishedYes

Fingerprint

Glioblastoma
Molecular Biology
Astrocytoma
Neoplasms
erbB-1 Genes
Mutation
Gene Amplification
Temporal Lobe
Epidermal Growth Factor Receptor
Biopsy
Genes

Keywords

  • CDKN2A/p16
  • De novo glioblastoma
  • EGFR
  • Genetics
  • Glioblastoma multiforme
  • P53
  • PTEN

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology
  • Neurology
  • Clinical Neurology
  • Physiology (medical)

Cite this

Molecular genetics of radiographically defined de novo glioblastoma multiforme. / Tortosa, A.; Ino, Y.; Odell, N.; Swilley, S.; Sasaki, Hikaru; Louis, D. N.; Henson, J. W.

In: Neuropathology and Applied Neurobiology, Vol. 26, No. 6, 01.12.2000, p. 544-552.

Research output: Contribution to journalArticle

Tortosa, A. ; Ino, Y. ; Odell, N. ; Swilley, S. ; Sasaki, Hikaru ; Louis, D. N. ; Henson, J. W. / Molecular genetics of radiographically defined de novo glioblastoma multiforme. In: Neuropathology and Applied Neurobiology. 2000 ; Vol. 26, No. 6. pp. 544-552.
@article{d1b3c89beab2427799e9b10ceacf107a,
title = "Molecular genetics of radiographically defined de novo glioblastoma multiforme",
abstract = "Glioblastoma multiforme (GBM) represents the final endpoint of anaplastic progression in astrocytomas. GBM which arise without clinical evidence of a prior low-grade astrocytoma (LGA) have been designated de novo GBM, and are thought to develop rapidly from initial tumour formation. However, a purely clinical definition of de novo GBM does not exclude a longstanding, asymptomatic low-grade tumour. This study therefore sought to determine the genetic features of a unique group of cases in which GBMs were documented to have arisen radiographically in defined period of time (radiographically defined de novo GBM). Clinical and genetic features were examined in a group of 11 patients with a histological diagnosis of high-grade astrocytoma at first biopsy and radiographically defined de novo GBM. The mean age of the patients at tumour diagnosis was 62 years (range 32-87). Six of 11 tumours arose in the temporal lobes. Eight of 11 tumours had epidermal growth factor receptor (EGFR) overexpression, and EGFR gene amplification was found in five of the six analysed cases. Overexpression of p53 was observed in only one tumour, and a TP53 mutation was present in this case. p16 immunostaining was undetectable in 10 cases, and homozygous deletion of CDKN2A was observed in four of the six studied tumours, pRb expression was lost in four tumours. Mutations in the PTEN gene were detected in two of six cases. The results in this unique group of cases confirms the prior hypothesis that the profile of genetic alterations in de novo GBM is distinct from that of GBM arising from a known LGA, and that these Specific genetic pathways promote the rapid development of CBM.",
keywords = "CDKN2A/p16, De novo glioblastoma, EGFR, Genetics, Glioblastoma multiforme, P53, PTEN",
author = "A. Tortosa and Y. Ino and N. Odell and S. Swilley and Hikaru Sasaki and Louis, {D. N.} and Henson, {J. W.}",
year = "2000",
month = "12",
day = "1",
doi = "10.1046/j.0305-1846.2000.00290.x",
language = "English",
volume = "26",
pages = "544--552",
journal = "Neuropathology and Applied Neurobiology",
issn = "0305-1846",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Molecular genetics of radiographically defined de novo glioblastoma multiforme

AU - Tortosa, A.

AU - Ino, Y.

AU - Odell, N.

AU - Swilley, S.

AU - Sasaki, Hikaru

AU - Louis, D. N.

AU - Henson, J. W.

PY - 2000/12/1

Y1 - 2000/12/1

N2 - Glioblastoma multiforme (GBM) represents the final endpoint of anaplastic progression in astrocytomas. GBM which arise without clinical evidence of a prior low-grade astrocytoma (LGA) have been designated de novo GBM, and are thought to develop rapidly from initial tumour formation. However, a purely clinical definition of de novo GBM does not exclude a longstanding, asymptomatic low-grade tumour. This study therefore sought to determine the genetic features of a unique group of cases in which GBMs were documented to have arisen radiographically in defined period of time (radiographically defined de novo GBM). Clinical and genetic features were examined in a group of 11 patients with a histological diagnosis of high-grade astrocytoma at first biopsy and radiographically defined de novo GBM. The mean age of the patients at tumour diagnosis was 62 years (range 32-87). Six of 11 tumours arose in the temporal lobes. Eight of 11 tumours had epidermal growth factor receptor (EGFR) overexpression, and EGFR gene amplification was found in five of the six analysed cases. Overexpression of p53 was observed in only one tumour, and a TP53 mutation was present in this case. p16 immunostaining was undetectable in 10 cases, and homozygous deletion of CDKN2A was observed in four of the six studied tumours, pRb expression was lost in four tumours. Mutations in the PTEN gene were detected in two of six cases. The results in this unique group of cases confirms the prior hypothesis that the profile of genetic alterations in de novo GBM is distinct from that of GBM arising from a known LGA, and that these Specific genetic pathways promote the rapid development of CBM.

AB - Glioblastoma multiforme (GBM) represents the final endpoint of anaplastic progression in astrocytomas. GBM which arise without clinical evidence of a prior low-grade astrocytoma (LGA) have been designated de novo GBM, and are thought to develop rapidly from initial tumour formation. However, a purely clinical definition of de novo GBM does not exclude a longstanding, asymptomatic low-grade tumour. This study therefore sought to determine the genetic features of a unique group of cases in which GBMs were documented to have arisen radiographically in defined period of time (radiographically defined de novo GBM). Clinical and genetic features were examined in a group of 11 patients with a histological diagnosis of high-grade astrocytoma at first biopsy and radiographically defined de novo GBM. The mean age of the patients at tumour diagnosis was 62 years (range 32-87). Six of 11 tumours arose in the temporal lobes. Eight of 11 tumours had epidermal growth factor receptor (EGFR) overexpression, and EGFR gene amplification was found in five of the six analysed cases. Overexpression of p53 was observed in only one tumour, and a TP53 mutation was present in this case. p16 immunostaining was undetectable in 10 cases, and homozygous deletion of CDKN2A was observed in four of the six studied tumours, pRb expression was lost in four tumours. Mutations in the PTEN gene were detected in two of six cases. The results in this unique group of cases confirms the prior hypothesis that the profile of genetic alterations in de novo GBM is distinct from that of GBM arising from a known LGA, and that these Specific genetic pathways promote the rapid development of CBM.

KW - CDKN2A/p16

KW - De novo glioblastoma

KW - EGFR

KW - Genetics

KW - Glioblastoma multiforme

KW - P53

KW - PTEN

UR - http://www.scopus.com/inward/record.url?scp=0034526611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034526611&partnerID=8YFLogxK

U2 - 10.1046/j.0305-1846.2000.00290.x

DO - 10.1046/j.0305-1846.2000.00290.x

M3 - Article

C2 - 11123721

AN - SCOPUS:0034526611

VL - 26

SP - 544

EP - 552

JO - Neuropathology and Applied Neurobiology

JF - Neuropathology and Applied Neurobiology

SN - 0305-1846

IS - 6

ER -